The Pharmacy and Poisons Board (PPB) of the Kenyan Health Ministry granted the certification following a rigorous audit of the company’s production facilities in Baddi, a company statement said.

Venus Remedies gets GMP certification from Kenya for production facilities in Baddi

With the renewal of recognition from DSIR and its ongoing efforts to combat antimicrobial resistance, Venus Remedies Limited solidifies its position as a leading research-driven pharmaceutical company, dedicated to excellence in research and bringing innovative medical solutions to address global he…

DSIR Recognition to Venus Remedies’ in-house R&D Unit

Venus Remedies surged 4.76% to Rs 168.35 after the company said that it has received good manufacturing practices (GMP) certification from Saudi Arabia for all its production facilities at its unit in Baddi, Himachal Pradesh.

Venus Remedies spurts after Baddi facility gets GMP certificate

The Saudi Food and Drug Authority (SFDA) granted the certification which includes first-time approval for pre-filled enoxaparin syringes and general injection facilities, the company said in a regulatory filing.

Venus Remedies gets good manufacturing certification from Saudi drug regulator

The certification is a testament to the company’s commitment to maintaining high-quality standards in its manufacturing processes, which will help it expand its presence in the Saudi Arabian market, Venus Remedies said.

Venus Remedies gains on Saudi certification to all production units in Baddi

Venus Remedies Ltd, Simplex Infrastructures Ltd, Delta Manufacturing Ltd and Indian Card Clothing Company Ltd are among the other gainers in the BSE’s ‘B’ group today, 23 February 2023.

Oriental Trimex Ltd leads gainers in ‘B’ group

Reliance, Tata Steel, Patel Engineering, Orient Cement, Adani Power, HG Infra, Venus Remedies, Elantas Beck, Lemon Tree

Stocks that will see action on February 23, 2023

Venus Remedies consolidated net profit declines 41.77% in the December 2022 quarter

Stocks in news: eMudhra, Tata Elxsi, Bata India, RVNL, Bharat Dynamics, Venus Remedies, HFCL and more

Stocks in news: eMudhra, Tata Elxsi, Bata India, RVNL and more

Stocks in news: LIC, IRCTC, Nykaa, Adani Enterprises, United Spirits, Glenmark Pharmaceuticals, Ethos, M&M, Venus Remedies, Inox Wind, Hindustan Copper, JSW Steel and more

Stocks in news: LIC, Nykaa, IRCTC, Adani Enterprises and more

The Panchkula-based company also reported a 16.81 per cent increase in operating profit, which went up from Rs 53.78 crore last fiscal to Rs 62.82 crore in 2021-22.

Venus Remedies registers 9.22% growth in sales for FY 2021-22

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Venus Remedies Limited is engaged in pharmaceutical product manufacturing business. The Company provides formulations and manufactures dosage injectables.